Loading
A phase 3 trial in pancreatic cancer, run by Sahlgrenska University Hospital, now recruiting.
Standard or Prolonged Neoadjuvant Chemotherapy Before Surgery for BR/LAPC is a phase 3, randomised interventional study registered as NCT06714604 by Sahlgrenska University Hospital, with a registry enrolment figure of 432 participants, started 2023-10-18 and due to reach its primary completion in 2032-12-31. Interventions recorded: FOLFIRINOX or gemcitabine-nab-paclitaxel; FOLFIRINOX or gemcitabine-nab-paclitaxel. Conditions listed: Locally Advanced Pancreatic Adenocarcinoma; Borderline Resectable Pancreatic Carcinoma; Pancreas Cancer; Neoadjuvant Chemotherapy; Surgery; Pancreatectomy. Primary outcome: Overall survival of all BR/LAPC patients; Overall survival of all resected BR/LAPC patients. Pancreatic eligibility wording from the registry: "* Borderline or locally advanced pancreatic adenocarcinoma at diagnosis according to National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines, version 1". Sites: Sweden. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Borderline resectable pancreatic ductal adenocarcinoma, Locally advanced unresectable pancreatic ductal adenocarcinoma, Resectable pancreatic ductal adenocarcinoma, Pancreatic cancer trials open today (registry snapshot and UK sites) and the tag pancreatic-deep-dive.
Shares Borderline resectable pancreatic ductal adenocarcinoma, Locally advanced unresectable pancreatic ductal adenocarcinoma, Resectable pancreatic ductal adenocarcinoma, Pancreatic cancer trials open today (registry snapshot and UK sites) and the tag pancreatic-deep-dive.
Shares Borderline resectable pancreatic ductal adenocarcinoma, Locally advanced unresectable pancreatic ductal adenocarcinoma, Resectable pancreatic ductal adenocarcinoma, Pancreatic cancer trials open today (registry snapshot and UK sites) and the tag pancreatic-deep-dive.
Shares Borderline resectable pancreatic ductal adenocarcinoma, Resectable pancreatic ductal adenocarcinoma, Pancreatic cancer trials open today (registry snapshot and UK sites) and the tag pancreatic-deep-dive.
Shares Borderline resectable pancreatic ductal adenocarcinoma, Resectable pancreatic ductal adenocarcinoma, Pancreatic cancer trials open today (registry snapshot and UK sites) and the tag pancreatic-deep-dive.
Shares Borderline resectable pancreatic ductal adenocarcinoma, Resectable pancreatic ductal adenocarcinoma, Pancreatic cancer trials open today (registry snapshot and UK sites) and the tag pancreatic-deep-dive.
Shares Locally advanced unresectable pancreatic ductal adenocarcinoma, Resectable pancreatic ductal adenocarcinoma, Pancreatic cancer trials open today (registry snapshot and UK sites) and the tag pancreatic-deep-dive.
Shares Borderline resectable pancreatic ductal adenocarcinoma, Locally advanced unresectable pancreatic ductal adenocarcinoma, Resectable pancreatic ductal adenocarcinoma, Pancreatic cancer trials open today (registry snapshot and UK sites) and the tag pancreatic-deep-dive.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/